Kancera AB
Records under this name other than the patents Kancera AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Showing 1 to 9 of 9 · Back to Kancera AB
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,440,992 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors Term ended Term ended Aug 23, 2026 · From the USPTO record | Term ended | Term ended Aug 23, 2026 | From the USPTO record |
| US 10,000,449 | Bisarylsulfonamides useful in the treatment of inflammation and cancer Lapsed on the fee record Ended Jun 19, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 19, 2026 | From the USPTO record |
| US 9,718,809 | Bisarylsulfonamides useful in the treatment of inflammation and cancer Lapsed on the fee record Ended Aug 1, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 1, 2025 | From the USPTO record |
| US 11,008,318 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity Lapsed on the fee record Ended May 18, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 18, 2025 | From the USPTO record |
| US 10,654,814 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity Lapsed on the fee record Ended May 19, 2024 · From the USPTO record | Lapsed on the fee record | Ended May 19, 2024 | From the USPTO record |
| US 9,266,952 | Antibodies against ROR1 and uses thereof Formerly held Lapsed on the fee record Ended Feb 23, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 23, 2024 | From the USPTO record |
| US 9,233,946 | Sulfonamide compounds Lapsed on the fee record Ended Jan 12, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 12, 2024 | From the USPTO record |
| US 10,512,634 | Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity Lapsed on the fee record Ended Dec 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 24, 2023 | From the USPTO record |
| US 9,150,647 | Biological inhibitors of ROR1 capable of inducing cell death Lapsed on the fee record Ended Oct 6, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 6, 2023 | From the USPTO record |